

Hemophilia of Georgia

Hemophilia Clinical Scientist Development Grant Policies and Rules

Introduction

Since 2003, Hemophilia of Georgia has directly funded physician researchers to conduct translational research of hemophilia and its complications. Each grant is for \$75,000 a year, renewable for up to five years, with an additional \$7,500 per year for indirect costs. The grant requires an 80% time commitment to hemophilia-related research.

Through this program, Hemophilia of Georgia hopes to help create the next generation of hemophilia researchers. This funding will allow a physician who has completed research training to advance to the status of an independent investigator. Our goal is for the achievements of these scientists to improve the lives of people with hemophilia.

Hemophilia of Georgia is a not-for-profit organization that serves people with inherited bleeding disorders. The organization is involved in several projects of regional, national, and international scope.

Eligibility

Applicants must have an MD degree and have a minimum of three years of research experience. Because the purpose of this grant is to further the development of beginning researchers, well-established hemophilia scientists (including recipients of NIH R01 or NSF grants) are not eligible to apply. Applicants must be U.S. citizens, have permanent resident status (hold an I-551), or be a non-citizen national.

Applicants must be sponsored by a non-federal public or private non-profit institution that conducts health related research within the U.S. and its possessions. A full-time faculty appointment is required throughout the award period.

Application

Applications are accepted year-round. Applicants must complete the grant application available in PDF and WORD formats on the Hemophilia of Georgia website (www.hog.org). One copy with original signatures should be mailed directly to the Hemophilia of Georgia office and a PDF copy submitted via email to gjcornett@hog.org. Incomplete applications will be returned to the applicant. On the next business day, applicants will be notified via e-mail of receipt of their application. Applicants will be notified in writing of the decision of the awards committee. Questions about the application process can be addressed to Hemophilia of Georgia's Vice President of Research and Public Policy, Jeff Cornett, via phone (770-518-8272) or e-mail (gjcornett@hog.org).

Mail the original application to:
Hemophilia Grant Application
Hemophilia of Georgia
8607 Roberts DR, STE 150
Sandy Springs, GA 30350-2237

A complete application will consist of the following:

- ❑ Completed Hemophilia Clinical Scientist Development Grant Application and Budget.
- ❑ A letter from the chairperson of the applicant's department describing the institution's commitment to the applicant's career development and providing assurance of adequate space and other facilities for conducting the proposed research. The chairperson must also outline a plan for allocating the applicant's responsibilities so that at least 80% of her or his time is spent on hemophilia-related research.
- ❑ Three letters of recommendation describing the scientific abilities and potential of the applicant.

The application documents must be typed in 12 point font. The completed application should maintain the format and layout shown in the PDF document. Do not submit applications in three ring binders or with index tabs.

Acceptable budget requests include researcher salary and fringe, equipment and supplies necessary for carrying out the research, salary for a technician/research assistant, up to \$1,000 for travel to hemophilia-related scientific meetings, and \$7,500 in indirect costs.

The following cannot be paid with Hemophilia of Georgia grant funding:

- secretarial or administrative salaries
- membership dues
- tuition, books and periodicals
- office and laboratory furniture
- office equipment and supplies including computers
- construction, renovation, or maintenance of buildings or laboratories
- expenditures made prior to the start of the grant.

Review Criteria

All applications that meet the eligibility requirements will be reviewed and rated. In addition to the quality of the research proposal, applications will be evaluated based on the applicant's qualifications, experience, and commitment to pursue a career in hemophilia-related research and the sponsoring institution's commitment to support the applicant in this endeavor.

Terms of Award

In addition to the terms described above, awards are granted based on the following:

Awards are paid to the sponsoring institution. Grant recipients must hold a full-time faculty position at the sponsoring institution throughout the award period and will notify Hemophilia of Georgia immediately of any change in their status. The grant award cannot be transferred to another institution without the approval of Hemophilia of Georgia.

Grant recipients are eligible for up to five years of funding. Each year of funding after the first is contingent upon approval by Hemophilia of Georgia of the recipient's Development Grant report and the availability of funds. In the event that a grant is terminated by the recipient or Hemophilia of Georgia, the sponsoring institution will receive only the amount of the award pro-rated to the date of cancellation. Hemophilia of Georgia will not be responsible for expenditures greater than the prorated amount.

Grant money will be paid monthly to the sponsoring institution and the check mailed to the address given on the application form.

During the grant year, minor changes are allowed in the budget. Specifically, grant recipients may move up to 10% of the amount allocated to one budget category to another category. Major changes to the budget require prior approval from Hemophilia of Georgia.

Recipients of funding will submit a Development Grant Report and Development Grant Financial Report in the month after the completion of each award year. A final grant and financial report will be due within one month after the completion of the fifth year of funding. Guidelines for these reports will be emailed to grant recipients. All unexpended funds must be returned to Hemophilia of Georgia.

Grant recipients can apply for future federal or non-federal research funding. They will immediately notify Hemophilia of Georgia of any additional salary or research support they receive and submit a revised budget. Budget overlaps with funding from other sources is not allowed.

Recipients are encouraged to report the progress of their research in journals and at professional meetings. Recipients will acknowledge the support of Hemophilia of Georgia in all publications of research conducted during the award period, including press releases. In addition, recipients will send Hemophilia of Georgia a copy of any abstracts or manuscripts produced.

Hemophilia of Georgia is not responsible for the conduct of the researcher. He or she is expected to remain under the direction of the sponsoring institution and abide by its

scientific and medical policies. Sponsoring institutions are expected to follow all NIH and HHS guidelines for research including those dealing with human and animal subjects, financial conflict of interest, and research misconduct.

So that Hemophilia of Georgia (HoG) can judge the effectiveness of the Hemophilia Clinical Scientist Development program, recipients must agree to inform HoG of their professional status, research support, and publications each year for the five years following the end of the award period.

All recipients and their sponsoring institutions accept the terms of Hemophilia of Georgia's patent policy:

1. All inventions made with the support, in whole or in part, of Hemophilia of Georgia Clinical Scientist Development Grant funds must be reported in a timely fashion to Hemophilia of Georgia.
2. Unless otherwise indicated or requested by the grantee institution, title to any invention shall reside in the grantee institution.
3. All inventions made with the support, in whole or in part, by this grant shall be reported by the grantee institution to Hemophilia of Georgia within one month of their disclosure to personnel at the grantee institution responsible for such matters. The grantee agrees to notify Hemophilia of Georgia immediately of the decision to apply for letters of patent or other legal protection for intellectual property. Hemophilia of Georgia agrees to keep all information regarding such applications confidential.

Unless prohibited by federal law, Hemophilia of Georgia reserves the right to share in any income and other economic benefits from an invention or discovery developed under this grant by entering into an agreement with the grantee institution at the time of such disclosure. Such agreement shall provide that income derived from the invention shall be distributed in proportion to the contributions by Hemophilia of Georgia, the grantee institution and, where applicable, other sponsoring agencies, after deductions of reasonable expenses incurred in obtaining intellectual property protection.

4. No patent or patent application shall be abandoned without first notifying Hemophilia of Georgia and giving Hemophilia of Georgia the opportunity to take title to the invention and to continue the patent or patent application at its own expense.
5. The grantee institution shall agree that if it or its licensee has not taken effective steps, within three years after a U.S. patent issues on an invention supported by Hemophilia of Georgia funds and administered by the institution, to bring that invention to the point of practical application, or has not made such invention available for licensing, Hemophilia of Georgia shall have the right to assume

- assignment of the patent, to cancel any existing licenses, and to grant new licenses.
6. If a grantee institution has no established patent policy or procedure for administering inventions, Hemophilia of Georgia shall have the right to determine the disposition of invention rights.
 7. If any invention is made with the joint support of Hemophilia of Georgia and other organizations, it is expected that all organizations will defer to the policies of the grantee institution. Royalty distribution shall be in accordance with the provision of this policy, with shares distributed to sponsoring agencies in proportion to their initial contribution. Should an exception be taken to this provision, the grantee institution, Hemophilia of Georgia, and other sponsoring agencies will confer to arrive at a mutually satisfactory disposition of invention rights.